secwatch.observer — SEC 8-K summary
======================================

Issuer:     LanzaTech Global, Inc. (LNZA)
CIK:        0001843724
Form:       8-K
Filed at:   2025-01-22T23:59:59+00:00
Accession:  0001628280-25-002081
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LanzaTech to spin out LanzaX synthetic biology unit as JV with Tharsis; appoints interim CFO
--------------------------------------------------------------------------------

- CFO Geoff Trukenbrod resigned effective Jan 21, 2025; Justin Pugh (FTI) appointed interim CFO.
- Plans to spin out LanzaX, its synbio platform, as a joint venture with Tharsis Capital.
- LanzaX will include 30+ employees and a portfolio of over 100 molecules.
- Expected cost savings of ~$8M annually; spin-out expected to complete in 2025.
- Move aims to accelerate synbio development and sharpen focus on core biorefining and SAF projects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1843724/000162828025002081/0001628280-25-002081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1843724/000162828025002081/amci-20250121.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-002081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer